Haemonetics (HAE) Stock Forecast, Price Target & Predictions
HAE Stock Forecast
Haemonetics stock forecast is as follows: an average price target of $107.00 (represents a 39.14% upside from HAE’s last price of $76.90) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
HAE Price Target
The average price target for Haemonetics (HAE) is $107.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $120.00 to $85.00. This represents a potential 39.14% upside from HAE's last price of $76.90.
HAE Analyst Ratings
According to 7 Wall Street analysts, Haemonetics's rating consensus is 'Buy'. The analyst rating breakdown for HAE stock is 1 'Strong Buy' (14.29%), 4 'Buy' (57.14%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Haemonetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 08, 2024 | Andrew Cooper | Raymond James | $120.00 | $74.83 | 60.36% | 56.05% |
| Sep 13, 2024 | Kristen Stewart | C.L. King | $116.00 | $73.26 | 58.34% | 50.85% |
| Sep 11, 2024 | Craig Bijou | Bank of America Securities | $85.00 | $71.61 | 18.69% | 10.53% |
| Jun 12, 2024 | Mike Matson | Needham | $112.00 | $83.41 | 34.28% | 45.64% |
The latest Haemonetics stock forecast, released on Nov 08, 2024 by Andrew Cooper from Raymond James, set a price target of $120.00, which represents a 60.36% increase from the stock price at the time of the forecast ($74.83), and a 56.05% increase from HAE last price ($76.90).
Haemonetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $120.00 | $108.25 |
| Last Closing Price | $76.90 | $76.90 | $76.90 |
| Upside/Downside | -100.00% | 56.05% | 40.77% |
In the current month, the average price target of Haemonetics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Haemonetics's last price of $76.90. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 08, 2024 | Raymond James | Strong Buy | Upgrade | |
| Sep 11, 2024 | Bank of America Securities | Neutral | Initialise | |
| Sep 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 10, 2024 | Citigroup | Underperform | Underperform | Hold |
| Sep 10, 2024 | BTIG | Buy | Initialise | |
| Aug 22, 2024 | Needham | Market Outperform | Market Outperform | Hold |
| Jun 12, 2024 | Needham | Hold | Buy | Upgrade |
| May 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| May 10, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 12, 2023 | William Blair | Outperform | Outperform | Hold |
| Jul 01, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Apr 26, 2022 | Needham | Hold | Downgrade |
Haemonetics's last stock rating was published by Raymond James on Nov 08, 2024. The company Upgrade its HAE rating from "null" to "Strong Buy".
Haemonetics Financial Forecast
Haemonetics Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $336.25M | $318.18M | $311.33M | $304.42M | $305.30M | $297.49M | $261.46M | $265.00M | - | $239.90M | $228.53M | $225.03M | $240.37M | $209.49M | $195.58M | $238.49M | $258.97M |
| Avg Forecast | $413.73M | $388.88M | $377.36M | $365.13M | $376.86M | $363.22M | $355.07M | $346.77M | $359.09M | $352.98M | $342.57M | $335.08M | $329.53M | $320.84M | $313.15M | $292.74M | $290.79M | $299.56M | $269.22M | $249.00M | $257.11M | $265.39M | $240.84M | $219.43M | $222.98M | $224.26M | $207.65M | $198.27M | $246.53M | $255.40M |
| High Forecast | $420.04M | $394.80M | $383.11M | $370.69M | $382.60M | $368.75M | $360.48M | $352.05M | $367.59M | $355.51M | $342.75M | $335.08M | $329.53M | $325.06M | $319.83M | $297.20M | $295.22M | $304.12M | $269.22M | $249.00M | $257.11M | $265.39M | $240.84M | $219.43M | $222.98M | $224.26M | $207.65M | $198.27M | $246.53M | $255.40M |
| Low Forecast | $408.41M | $383.87M | $372.51M | $360.43M | $372.01M | $358.55M | $350.50M | $342.31M | $355.69M | $349.86M | $342.39M | $335.08M | $329.53M | $318.18M | $309.03M | $288.98M | $287.05M | $295.71M | $269.22M | $249.00M | $257.11M | $265.39M | $240.84M | $219.43M | $222.98M | $224.26M | $207.65M | $198.27M | $246.53M | $255.40M |
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.02% | 1.06% | 1.05% | 1.02% | 1.10% | 1.05% | 1.03% | - | 1.00% | 1.04% | 1.01% | 1.07% | 1.01% | 0.99% | 0.97% | 1.01% |
Haemonetics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $329.53M, with a low forecast of $329.53M, and a high forecast of $329.53M. HAE's average Quarter revenue forecast represents a -2.00% decrease compared to the company's last Quarter revenue of $336.25M (Dec 23).
Haemonetics EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $69.51M | $35.30M | $53.66M | $59.11M | $66.85M | $69.79M | $53.21M | $31.26M | - | $48.04M | $7.22M | $536.00K | $39.31M | $48.16M | $33.47M | $54.77M | $69.84M |
| Avg Forecast | $84.95M | $79.85M | $77.49M | $74.97M | $77.38M | $74.58M | $72.91M | $71.20M | $73.73M | $72.48M | $70.34M | $68.81M | $48.82M | $65.88M | $64.30M | $60.11M | $44.38M | $74.38M | $56.43M | $52.19M | $40.34M | $55.63M | $50.48M | $45.99M | $965.37K | $47.01M | $43.52M | $41.56M | $57.77M | $53.53M |
| High Forecast | $86.25M | $81.07M | $78.67M | $76.12M | $78.56M | $75.72M | $74.02M | $72.29M | $75.48M | $73.00M | $70.38M | $68.81M | $58.58M | $66.75M | $65.67M | $61.03M | $53.25M | $89.25M | $56.43M | $52.19M | $48.41M | $55.63M | $50.48M | $45.99M | $1.16M | $47.01M | $43.52M | $41.56M | $69.33M | $53.53M |
| Low Forecast | $83.86M | $78.82M | $76.49M | $74.01M | $76.39M | $73.62M | $71.97M | $70.29M | $73.04M | $71.84M | $70.30M | $68.81M | $39.05M | $65.33M | $63.46M | $59.34M | $35.50M | $59.50M | $56.43M | $52.19M | $32.28M | $55.63M | $50.48M | $45.99M | $772.30K | $47.01M | $43.52M | $41.56M | $46.22M | $53.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 0.55% | 0.89% | 1.33% | 0.90% | 1.24% | 1.02% | 0.77% | - | 0.95% | 0.16% | 0.56% | 0.84% | 1.11% | 0.81% | 0.95% | 1.30% |
2 analysts predict HAE's average Quarter EBITDA for Mar 24 to be $48.82M, with a high of $58.58M and a low of $39.05M. This is -29.77% lower than Haemonetics's previous annual EBITDA (Dec 23) of $69.51M.
Haemonetics Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $31.24M | $24.91M | $41.04M | $29.38M | $32.94M | $33.20M | $19.88M | $9.74M | - | $14.86M | $-4.45M | $-11.04M | $31.88M | $48.10M | $10.53M | $17.62M | $29.89M |
| Avg Forecast | $90.09M | $82.47M | $75.15M | $69.82M | $75.19M | $69.20M | $65.01M | $60.55M | $65.94M | $59.97M | $54.99M | $51.52M | $10.80M | $48.24M | $45.49M | $37.04M | $9.82M | $7.74K | $34.74M | $26.30M | $8.93M | $37.83M | $31.24M | $23.20M | $-14.50M | $33.74M | $26.05M | $21.36M | $18.59M | $39.04M |
| High Forecast | $91.87M | $84.10M | $76.64M | $71.20M | $76.68M | $70.57M | $66.29M | $61.75M | $66.45M | $60.98M | $55.09M | $51.53M | $12.97M | $49.73M | $49.58M | $37.78M | $11.79M | $9.29K | $34.74M | $26.30M | $10.72M | $37.83M | $31.24M | $23.20M | $-11.60M | $33.74M | $26.05M | $21.36M | $22.31M | $39.04M |
| Low Forecast | $88.58M | $81.09M | $73.89M | $68.65M | $73.94M | $68.04M | $63.92M | $59.54M | $64.91M | $59.47M | $54.89M | $51.51M | $8.64M | $47.25M | $42.43M | $36.42M | $7.86M | $6.20K | $34.74M | $26.30M | $7.14M | $37.83M | $31.24M | $23.20M | $-17.40M | $33.74M | $26.05M | $21.36M | $14.87M | $39.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.55% | 1.11% | 2.99% | 4254.68% | 0.96% | 0.76% | 1.09% | - | 0.48% | -0.19% | 0.76% | 0.94% | 1.85% | 0.49% | 0.95% | 0.77% |
Haemonetics's average Quarter net income forecast for Mar 24 is $10.80M, with a range of $8.64M to $12.97M. HAE's average Quarter net income forecast represents a -65.42% decrease compared to the company's last Quarter net income of $31.24M (Dec 23).
Haemonetics SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $111.71M | $104.90M | $93.48M | $97.38M | $94.66M | $92.41M | $92.23M | $91.84M | - | $75.78M | $91.22M | $83.71M | $73.45M | $71.70M | $69.54M | $78.57M | $78.27M |
| Avg Forecast | $133.40M | $125.39M | $121.68M | $117.73M | $121.51M | $117.12M | $114.49M | $111.81M | $115.78M | $113.82M | $110.46M | $108.04M | $101.87M | $103.45M | $100.97M | $94.39M | $92.61M | $78.14M | $86.17M | $79.69M | $84.19M | $84.94M | $77.08M | $70.23M | $78.16M | $71.78M | $66.46M | $63.46M | $82.88M | $81.74M |
| High Forecast | $135.44M | $127.30M | $123.53M | $119.53M | $123.37M | $118.90M | $116.23M | $113.52M | $118.53M | $114.63M | $110.52M | $108.04M | $122.24M | $104.81M | $103.13M | $95.83M | $111.13M | $93.77M | $86.17M | $79.69M | $101.03M | $84.94M | $77.08M | $70.23M | $93.79M | $71.78M | $66.46M | $63.46M | $99.46M | $81.74M |
| Low Forecast | $131.69M | $123.78M | $120.11M | $116.22M | $119.95M | $115.61M | $113.02M | $110.37M | $114.69M | $112.81M | $110.40M | $108.04M | $81.49M | $102.60M | $99.64M | $93.18M | $74.09M | $62.51M | $86.17M | $79.69M | $67.35M | $84.94M | $77.08M | $70.23M | $62.53M | $71.78M | $66.46M | $63.46M | $66.30M | $81.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.04% | 0.99% | 1.05% | 1.21% | 1.07% | 1.16% | 1.09% | - | 0.98% | 1.30% | 1.07% | 1.02% | 1.08% | 1.10% | 0.95% | 0.96% |
Haemonetics's average Quarter SG&A projection for Mar 24 is $101.87M, based on 2 Wall Street analysts, with a range of $81.49M to $122.24M. The forecast indicates a -8.81% fall compared to HAE last annual SG&A of $111.71M (Dec 23).
Haemonetics EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.62 | $0.49 | $0.81 | $0.58 | $0.65 | $0.65 | $0.39 | $0.19 | - | $0.29 | $-0.09 | $-0.22 | $0.63 | $0.95 | $0.21 | $0.34 | $0.59 |
| Avg Forecast | $1.76 | $1.61 | $1.47 | $1.36 | $1.47 | $1.35 | $1.27 | $1.18 | $1.29 | $1.17 | $1.07 | $1.01 | $0.89 | $0.94 | $0.89 | $0.72 | $0.70 | $0.82 | $0.67 | $0.51 | $0.60 | $0.73 | $0.61 | $0.45 | $0.67 | $0.65 | $0.51 | $0.41 | $0.73 | $0.76 |
| High Forecast | $1.79 | $1.64 | $1.50 | $1.39 | $1.50 | $1.38 | $1.29 | $1.21 | $1.30 | $1.19 | $1.08 | $1.01 | $0.89 | $0.97 | $0.97 | $0.74 | $0.72 | $0.83 | $0.67 | $0.51 | $0.60 | $0.73 | $0.61 | $0.45 | $0.67 | $0.65 | $0.51 | $0.41 | $0.73 | $0.76 |
| Low Forecast | $1.73 | $1.58 | $1.44 | $1.34 | $1.44 | $1.33 | $1.25 | $1.16 | $1.27 | $1.16 | $1.07 | $1.01 | $0.89 | $0.92 | $0.83 | $0.71 | $0.69 | $0.80 | $0.67 | $0.51 | $0.60 | $0.73 | $0.61 | $0.45 | $0.67 | $0.65 | $0.51 | $0.41 | $0.73 | $0.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.55% | 1.12% | 0.82% | 0.80% | 0.96% | 0.76% | 0.32% | - | 0.48% | -0.19% | -0.33% | 0.96% | 1.88% | 0.51% | 0.47% | 0.78% |
According to 2 Wall Street analysts, Haemonetics's projected average Quarter EPS for Mar 24 is $0.89, with a low estimate of $0.89 and a high estimate of $0.89. This represents a 43.84% increase compared to HAE previous annual EPS of $0.62 (Dec 23).
Haemonetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKYA | Akoya Biosciences | $2.54 | $4.83 | 90.16% | Buy |
| TFX | Teleflex | $178.28 | $254.50 | 42.75% | Buy |
| ANGO | AngioDynamics | $9.26 | $13.00 | 40.39% | Buy |
| HAE | Haemonetics | $82.07 | $107.00 | 30.38% | Buy |
| ATRC | AtriCure | $31.50 | $39.67 | 25.94% | Buy |
| ATR | AptarGroup | $163.09 | $200.00 | 22.63% | Buy |
| COO | Cooper Companies | $94.49 | $115.00 | 21.71% | Buy |
| ALC | Alcon | $85.54 | $104.00 | 21.58% | Buy |
| ICUI | ICU Medical | $157.17 | $190.50 | 21.21% | Buy |
| WST | West Pharmaceutical Services | $334.26 | $393.00 | 17.57% | Buy |
| MMSI | Merit Medical Systems | $99.00 | $108.83 | 9.93% | Buy |
| NVST | Envista | $19.24 | $20.29 | 5.46% | Hold |
| HOLX | Hologic | $72.26 | $74.20 | 2.68% | Buy |
| RMD | ResMed | $242.62 | $233.50 | -3.76% | Hold |